Atreca Inc.

6.89+0.2200+3.30%Vol 205.76K1Y Perf -46.14%
Sep 23rd, 2021 13:52 DELAYED
BID6.83 ASK6.87
Open6.67 Previous Close6.67
Pre-Market- After-Market-
 - -%  - -
Target Price
21.33 
Analyst Rating
Strong Buy 1.00
Potential %
211.39 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
13.49 
Earnings Rating
Market Cap254.20M 
Earnings Date
11th Nov 2021
Alpha-0.01 Standard Deviation0.26
Beta0.04 

Today's Price Range

6.507.00

52W Range

4.8020.29

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
9.17%
1 Month
14.02%
3 Months
-19.74%
6 Months
-54.44%
1 Year
-46.14%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BCEL6.890.22003.30
AAPL146.961.11000.76
GOOG2 843.1824.41000.87
MSFT300.111.53000.51
XOM57.091.88003.41
WFC48.101.02002.17
JNJ165.541.61000.98
FB346.723.51001.02
GE103.715.17005.25
JPM161.685.77003.70
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.71-0.72-1.41
Q01 2021-0.65-0.70-7.69
Q04 2020-0.63-0.630.00
Q03 2020-0.60-0.66-10.00
Q02 2020-0.77-0.717.79
Q01 2020-0.74-0.731.35
Q04 2019-0.64-0.72-12.50
Q03 2019-0.73-0.5721.92
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date11th Nov 2021
Estimated EPS Next Report-0.75
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume205.76K
Shares Outstanding36.89M
Shares Float22.38M
Trades Count1.58K
Dollar Volume5.64M
Avg. Volume546.84K
Avg. Weekly Volume499.22K
Avg. Monthly Volume359.75K
Avg. Quarterly Volume999.92K

Atreca Inc. (NASDAQ: BCEL) stock closed at 6.67 per share at the end of the most recent trading day (a -0.89% change compared to the prior day closing price) with a volume of 1.23M shares and market capitalization of 254.20M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 128 people. Atreca Inc. CEO is John A. Orwin.

The one-year performance of Atreca Inc. stock is -46.14%, while year-to-date (YTD) performance is -58.7%. BCEL stock has a five-year performance of %. Its 52-week range is between 4.8 and 20.29, which gives BCEL stock a 52-week price range ratio of 13.49%

Atreca Inc. currently has a PE ratio of -2.30, a price-to-book (PB) ratio of 1.17, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -47.47%, a ROC of -55.93% and a ROE of -54.47%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Atreca Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.75 for the next earnings report. Atreca Inc.’s next earnings report date is 11th Nov 2021.

The consensus rating of Wall Street analysts for Atreca Inc. is Strong Buy (1), with a target price of $21.33, which is +211.39% compared to the current price. The earnings rating for Atreca Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Atreca Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Atreca Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.85, ATR14 : 0.39, CCI20 : 178.98, Chaikin Money Flow : 0.16, MACD : 0.06, Money Flow Index : 72.36, ROC : 8.99, RSI : 59.54, STOCH (14,3) : 91.67, STOCH RSI : 0.87, UO : 61.80, Williams %R : -8.33), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Atreca Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (100.00 %)
9 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Atreca Inc.

Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

CEO: John A. Orwin

Telephone: +1 650 595-2595

Address: 450 East Jamie Court, South San Francisco 94080, CA, US

Number of employees: 128

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

80%20%

Bearish Bullish

65%35%

Bearish Bullish

61%39%

News

Stocktwits